MedTrace Logo

Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute Myeloid Leukemia Patients

NCT01889407 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 94

Last updated 2015-04-21

No results posted yet for this study

Summary

Whether Idarubicin can overcomes multidrug resistant 1 induced chemoresistance with higher induction remission rate than daunorubicin in de novo acute myeloid leukemia patients.Whether induction therapy with IA regimen has a higher remission quality with AML patients than that of DA regimen in high MDR1 expression AML patients.

Conditions

Interventions

DRUG

Idarubicin

8 mg/m2, iv drip on days 1-3

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Principal Investigators

  • Bing Xu, M.D · Department of Hematology, Nanfang Hospital, The Southern Medical University

Eligibility

Min Age
14 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01889407 on ClinicalTrials.gov